Literature DB >> 35852913

Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Yaya Kassogue1,2,3, Brehima Diakite1,2,3, Mamoudou Maiga2,3,4, Oumar Kassogue2, Issa Konate3,5, Kadidiatou Tamboura5, Fousseyni Diarra2, Zoumana Diarra6, Mahamadou Karamoko Sawadogo6, Yaya Goita7,8, Sidi Boula Sissoko3,9, Adama Seydou Sissoko3,10, Nouhoum Guirou3,11, Hind Dehbi12,13, Sellama Nadifi12,13, Sekou Bah8,14, Cheick Bougadari Traore1,2,3, Bakarou Kamate1,2,3, Sounkalo Dao3,5, Guimogo Dolo2,3.   

Abstract

OBJECTIVES: The main objective of this study was to evaluate the effect of CYP2B6 and CYP3A4 polymorphisms on the virological and immunologic responses of HIV patients. A total of 153 HIV-positive patients were enlisted for the study. PATIENTS AND METHODS: Viral load and median CD4 T cell counts were evaluated at baseline and month 6 (M6). Samples were identified using TaqMan genotyping assays.
RESULTS: The AG in CYP2B6 rs2279343 was associated with VLS compared to homozygous AA. In the dominant model, the AG/GG genotypes were associated with VLS compared to the AA genotype. Moreover, in overdominant model, the AG genotype was associated with VLS compared to AA/GG. Regarding immunological response, only the AG in SNP rs2279343 CYP2B6 was associated with an increase in CD4 cell count between baseline and M6. In CYP2B6 rs3745274, the CD4 cell count at M6 was higher than that of baseline for GG carriers and for GT carriers. In CYP3A4 rs2740574, the TC carriers showed a higher median CD4 count at M6 compared to that of the baseline count, as well as for CC carriers. The best genotypes combination associated with CD4 cell count improvement were AA/AG in SNP rs2279343 and GG/GT in SNP rs3745274.
CONCLUSION: Our findings support the fact that CYP2B6 rs2279343 could help in the prediction of VLS and both SNPs rs3745274 and rs2279343 in CYP2B6 and CYP3A4 rs2740574 were associated with immune recovery in Malian HIV-positive patients.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35852913      PMCID: PMC7613628          DOI: 10.1097/FPC.0000000000000477

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.000


  38 in total

1.  Increased transcriptional activity of the CYP3A4*1B promoter variant.

Authors:  B Amirimani; B Ning; A C Deitz; B L Weber; F F Kadlubar; T R Rebbeck
Journal:  Environ Mol Mutagen       Date:  2003       Impact factor: 3.216

2.  Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Authors:  Anne F Luetkemeyer; Susan L Rosenkranz; Darlene Lu; Beatriz Grinsztejn; Jorge Sanchez; Michael Ssemmanda; Ian Sanne; Helen McIlleron; Diane V Havlir; David W Haas
Journal:  Clin Infect Dis       Date:  2015-02-26       Impact factor: 9.079

3.  Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Authors:  Chonlaphat Sukasem; Tim R Cressey; Pattamawan Prapaithong; Yardpiroon Tawon; Ekawat Pasomsub; Chutatip Srichunrusami; Thawinee Jantararoungtong; Marc Lallement; Wasun Chantratita
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

4.  CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.

Authors:  Riaan Reay; Collet Dandara; Michelle Viljoen; Malie Rheeders
Journal:  OMICS       Date:  2017-08

5.  Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases.

Authors:  Sandi L Navarro; Misty R Saracino; Karen W Makar; Sushma S Thomas; Lin Li; Yingye Zheng; Lisa Levy; Yvonne Schwarz; Jeannette Bigler; John D Potter; Johanna W Lampe
Journal:  J Nutrigenet Nutrigenomics       Date:  2011-05-28

6.  Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Authors:  Félix Gutiérrez; Andrés Navarro; Sergio Padilla; Rosa Antón; Mar Masiá; Joaquín Borrás; Alberto Martín-Hidalgo
Journal:  Clin Infect Dis       Date:  2005-10-19       Impact factor: 9.079

7.  Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Authors:  M Rotger; H Tegude; S Colombo; M Cavassini; H Furrer; L Décosterd; J Blievernicht; T Saussele; H F Günthard; M Schwab; M Eichelbaum; A Telenti; U M Zanger
Journal:  Clin Pharmacol Ther       Date:  2007-01-18       Impact factor: 6.875

8.  Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.

Authors:  Sandra G Heil; Marchina E van der Ende; Paul W Schenk; Ilse van der Heiden; Jan Lindemans; David Burger; Ron H N van Schaik
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

Review 9.  PharmVar GeneFocus: CYP2B6.

Authors:  Zeruesenay Desta; Ahmed El-Boraie; Li Gong; Andrew A Somogyi; Volker M Lauschke; Collet Dandara; Kathrin Klein; Neil A Miller; Teri E Klein; Rachel F Tyndale; Michelle Whirl-Carrillo; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-03-11       Impact factor: 6.903

10.  Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Authors:  Sabina Mugusi; Eliford Ngaimisi; Mohammed Janabi; Ferdinand Mugusi; Omary Minzi; Eric Aris; Muhammad Bakari; Leif Bertilsson; Juergen Burhenne; Eric Sandstrom; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2018-07-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.